Synlogic and Caldera Therapeutics Announce Merger Agreement
Synlogic (SYBX) has signed a definitive merger agreement with Caldera Therapeutics, in an all-stock transaction that will result in both companies becoming subsidiaries of the newly formed holding company, also named Caldera. The combined entity plans to seek listing on Nasdaq under the ticker symbol 'CALD'. To support this move, Caldera arranged for a private placement expected to raise $278 million from healthcare-focused institutional investors and mutual funds. The merger aims to accelerate development of CLD-423, an investigational bispecific antibody in Phase I trials targeting inflammatory bowel disease. The combined company's financial resources are projected to sustain operations through 2029. Caldera CEO Praveen Tipirneni highlighted the molecule’s potential and the strategic value of this merger for advancing their pipeline. The transaction is subject to shareholder approval and customary closing conditions, with a target completion date in early 2027.